Phase 3 Trial of EB-101 Cell Therapy Seeks to Complete Enrollment This Year

Phase 3 Trial of EB-101 Cell Therapy Seeks to Complete Enrollment This Year

284344

Phase 3 Trial of EB-101 Cell Therapy Seeks to Complete Enrollment This Year

Abeona Therapeutics will proceed with enrollment for its pivotal Phase 3 study of EB-101 as a treatment for recessive dystrophic epidermolysis bullosa (RDEB), following a meeting with the U.S. Food and Drug Administration (FDA). “We appreciate the clarity provided by the FDA and we are pleased to be aligned with the Agency on the co-primary endpoints [goals] for the Phase 3 VIITAL study,” Michael Amoroso, Abeona’s principal executive and chief operating officer, said in a…

You must be logged in to read/download the full post.